We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
-7.84%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$375M
AUM Growth
-$122M
Cap. Flow
-$59.9M
Cap. Flow %
-16%
Top 10 Hldgs %
61.48%
Holding
38
New
4
Increased
8
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
OLMA icon
Olema Pharmaceuticals
OLMA
+$14.2M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$10.5M
3
CBAY
Cymabay Therapeutics
CBAY
+$8.1M
4
GPCR icon
Structure Therapeutics
GPCR
+$7.44M
5
VKTX icon
Viking Therapeutics
VKTX
+$4.65M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$47.8M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$38.6M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$23.9M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$5.52M
5
KALV
KalVista Pharmaceuticals
KALV
+$1.88M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MORF
26
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$4.58M 1.22%
+200,000
New +$10.5M
ADAP
27
DELISTED
Adaptimmune Therapeutics
ADAP
$3.97M 1.06%
5,095,912
– –
VRDN icon
28
Viridian Therapeutics
VRDN
$2.61B
$3.92M 1.05%
255,323
– –
PHAT icon
29
Phathom Pharmaceuticals
PHAT
$743M
$3.6M 0.96%
347,332
+65,000
+23% +$892K
VKTX icon
30
Viking Therapeutics
VKTX
$3.75B
$3.6M 0.96%
+325,000
New +$4.65M
INZY
31
DELISTED
Inozyme Pharma
INZY
$1.37M 0.37%
326,921
– –
HARP
32
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$1.29M 0.34%
319,670
-1
-0% -$7
EWTX icon
33
Edgewise Therapeutics
EWTX
$4.64B
– –
-712,798
Closed -$5.52M
VTYX
34
DELISTED
Ventyx Biosciences
VTYX
– –
-31,747
Closed -$1.04M
RETA
35
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-234,478
Closed -$23.9M
KDNY
36
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-1,003,406
Closed -$38.6M
ISEE
37
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-1,214,662
Closed -$47.8M
ONCR
38
DELISTED
Oncorus, Inc.
ONCR
– –
-2,377,031
Closed -$96.3K
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q3 2023 Portfolio in Review

As of Q3 2023, MPM BioImpact held 38 positions worth $375M, down 25% from $497M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

MPM BioImpact withdrew a net $59.9M in Q3 2023, closing 6 positions and reducing 6 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $47.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, MPM BioImpact opened a new position in Morphic Holding, Inc. Common Stock worth $4.58M.

  • MPM BioImpact's largest Q3 2023 buy was Morphic Holding, Inc. Common Stock: 200,000 shares worth $4.58M.
  • MPM BioImpact added most to Olema Pharmaceuticals in Q3 2023, an estimated $14.2M increase.
  • MPM BioImpact's biggest Q3 2023 reduction was KalVista Pharmaceuticals, cutting an estimated $1.88M.
  • MPM BioImpact fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $47.8M.
  • MPM BioImpact's ten largest holdings make up 61% of its $375M portfolio in Q3 2023.
  • MPM BioImpact opened 4 new positions and closed 6 in Q3 2023.
  • MPM BioImpact's portfolio value fell 25% quarter-over-quarter to $375M.

Based on MPM BioImpact's 13F filing for Q3 2023, filed 14 Nov 2023.